MX2022006251A - Analogos de insulina novedosos y usos de estos. - Google Patents

Analogos de insulina novedosos y usos de estos.

Info

Publication number
MX2022006251A
MX2022006251A MX2022006251A MX2022006251A MX2022006251A MX 2022006251 A MX2022006251 A MX 2022006251A MX 2022006251 A MX2022006251 A MX 2022006251A MX 2022006251 A MX2022006251 A MX 2022006251A MX 2022006251 A MX2022006251 A MX 2022006251A
Authority
MX
Mexico
Prior art keywords
insulin analogues
analogues
novel insulin
diabetes
medical conditions
Prior art date
Application number
MX2022006251A
Other languages
English (en)
Inventor
Helle Birk Olsen
Jeppe Sturis
Kjeldsen Thomas Børglum
Mathias Norrman
Frantisek Hubalek
Madsen, (Fallecido) Peter
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2022006251A publication Critical patent/MX2022006251A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención pertenece al campo terapéutico de los fármacos para las afecciones médicas relacionadas con la diabetes. Más específicamente, la invención se refiere a análogos de insulina de la insulina humana. La invención proporciona composiciones farmacéuticas que comprenden tales análogos de insulina y los usos de tales análogos para el tratamiento o prevención de afecciones médicas relacionadas con la diabetes.
MX2022006251A 2019-12-11 2020-12-10 Analogos de insulina novedosos y usos de estos. MX2022006251A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19215315 2019-12-11
PCT/EP2020/085541 WO2021116292A1 (en) 2019-12-11 2020-12-10 Novel insulin analogues and uses thereof

Publications (1)

Publication Number Publication Date
MX2022006251A true MX2022006251A (es) 2022-06-22

Family

ID=68886882

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022006251A MX2022006251A (es) 2019-12-11 2020-12-10 Analogos de insulina novedosos y usos de estos.
MX2023000398A MX2023000398A (es) 2019-12-11 2022-05-24 Analogos de insulina novedosos y usos de estos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023000398A MX2023000398A (es) 2019-12-11 2022-05-24 Analogos de insulina novedosos y usos de estos.

Country Status (16)

Country Link
US (3) US11498951B2 (es)
EP (1) EP4073097B1 (es)
JP (2) JP6995284B2 (es)
KR (1) KR102427426B1 (es)
CN (1) CN114787184A (es)
AR (1) AR120717A1 (es)
AU (1) AU2020402135A1 (es)
BR (1) BR112022009510A2 (es)
CA (1) CA3159114A1 (es)
CL (1) CL2023000086A1 (es)
CO (1) CO2022007273A2 (es)
IL (1) IL292762A (es)
MX (2) MX2022006251A (es)
PE (1) PE20221260A1 (es)
TW (1) TWI773009B (es)
WO (1) WO2021116292A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201717998A (zh) 2015-08-25 2017-06-01 諾佛 儂迪克股份有限公司 新穎胰島素衍生物及其醫學用途
BR112022009510A2 (pt) * 2019-12-11 2022-08-16 Novo Nordisk As Análogo de insulina, composição farmacêutica, e, método de tratamento, prevenção ou alívio de uma doença ou distúrbio ou condição
KR20230057686A (ko) 2021-10-22 2023-05-02 주식회사 엘지에너지솔루션 캡 어셈블리 및 이를 포함하는 이차 전지

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
JP3122128B2 (ja) 1989-12-21 2001-01-09 ノボ ノルディスク アクティーゼルスカブ ペプチド製剤
BR9407508A (pt) 1993-09-17 1997-01-07 Novo Nordisk As Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento
ZA954983B (en) 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5922678A (en) 1996-06-28 1999-07-13 Eli Lilly And Company Methods for treating diabetes
JP4187796B2 (ja) 1996-12-20 2008-11-26 ノボ ノルディスク アクティーゼルスカブ 酵母で発現されたｎ末端伸長タンパク質
IL131796A0 (en) 1997-03-20 2001-03-19 Novo Nordisk As Zinc free insulin crystals for use in pulmonary compositions
CN1276731A (zh) 1997-10-24 2000-12-13 伊莱利利公司 不溶性胰岛素组合物
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
WO2005054291A1 (en) 2003-12-03 2005-06-16 Novo Nordisk A/S Single-chain insulin
WO2006097521A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
ATE482977T1 (de) 2006-02-27 2010-10-15 Novo Nordisk As Insulinderivate
WO2007104738A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
ITRG20070003A1 (it) 2007-07-17 2009-01-18 Salvatore Lucifora Metodo e sistema informatico per analizzare le prestazioni e dimensionare una cella underlay/overlay di un sistema di telecomunicazione cellulare
ES2558930T3 (es) 2007-08-13 2016-02-09 Novo Nordisk A/S Análogos de la insulina de acción rápida
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
WO2009022013A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2910571B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
ES2563553T3 (es) 2008-04-01 2016-03-15 Novo Nordisk A/S Conjugados de insulina-albúmina
ES2611040T3 (es) 2009-06-30 2017-05-04 Novo Nordisk A/S Derivados de insulina
CN102665676B (zh) 2009-11-02 2015-04-01 诺沃-诺迪斯克有限公司 非共价结合的白蛋白和酰化胰岛素的药物溶液
US8815798B2 (en) 2010-06-23 2014-08-26 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
CA2805902A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
JP2013540771A (ja) 2010-10-15 2013-11-07 ノヴォ ノルディスク アー／エス 新規ｎ末端修飾インスリン誘導体
WO2012171994A1 (en) 2011-06-15 2012-12-20 Novo Nordisk A/S Multi substituted insulins
EP2771026A4 (en) 2011-10-27 2015-08-05 Univ Case Western Reserve QUICKLY ULTRA-CONCENTRATED INSULIN ANALOG FORMULATIONS
RU2014127270A (ru) 2011-12-15 2016-02-10 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Аналог человеческого инсулина и его ацилированное производное
US20160024169A1 (en) 2013-03-14 2016-01-28 Indiana University Research And Technology Corporation Insulin-incretin conjugates
AU2014329567B2 (en) 2013-10-04 2019-07-25 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US20190010206A1 (en) * 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
TW201717998A (zh) * 2015-08-25 2017-06-01 諾佛 儂迪克股份有限公司 新穎胰島素衍生物及其醫學用途
CN105440125B (zh) 2015-11-25 2019-09-24 华润昂德生物药业有限公司 地特胰岛素或其类似物的制备方法
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
BR112022009510A2 (pt) * 2019-12-11 2022-08-16 Novo Nordisk As Análogo de insulina, composição farmacêutica, e, método de tratamento, prevenção ou alívio de uma doença ou distúrbio ou condição

Also Published As

Publication number Publication date
AR120717A1 (es) 2022-03-09
JP2021091685A (ja) 2021-06-17
CO2022007273A2 (es) 2022-08-19
EP4073097A1 (en) 2022-10-19
EP4073097B1 (en) 2024-07-03
TWI773009B (zh) 2022-08-01
US11498951B2 (en) 2022-11-15
AU2020402135A1 (en) 2022-06-02
JP2021119193A (ja) 2021-08-12
BR112022009510A2 (pt) 2022-08-16
US20210179685A1 (en) 2021-06-17
MX2023000398A (es) 2023-02-02
KR20210141748A (ko) 2021-11-23
CN114787184A (zh) 2022-07-22
IL292762A (en) 2022-07-01
PE20221260A1 (es) 2022-08-16
US20240141011A1 (en) 2024-05-02
JP6995284B2 (ja) 2022-01-14
TW202136289A (zh) 2021-10-01
CL2023000086A1 (es) 2023-08-04
CA3159114A1 (en) 2021-06-17
KR102427426B1 (ko) 2022-08-01
US20230192801A1 (en) 2023-06-22
WO2021116292A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
MX368387B (es) A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22.
MX2023000398A (es) Analogos de insulina novedosos y usos de estos.
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
PH12019501363A1 (en) Insulin containing pharmaceutical compositions
EA201101518A1 (ru) Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии
PH12019502655A1 (en) Acylated insulin compound
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
MX2022009523A (es) Formulaciones farmaceuticas.
JOP20210201A1 (ar) مركب لخفض جلوكوز الدم
MX2023010328A (es) Composiciones de medicamentos a base de peptido de colageno y metodos y dispositivos para su produccion y uso.
RU2017120184A (ru) Лекарства для замедления течения болезни паркинсона
CR20220641A (es) Compuestos de insulina acilada de acción temporal prolongada
MX2021010988A (es) Derivados de insulina sensibles a la glucosa.
MX2021012579A (es) Composiciones farmaceuticas a base de peptidos de colageno y dispositivos y metodos de produccion y uso de los mismos.
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
EA201990419A1 (ru) Слаборастворимый комплекс или его сольват, фармацевтическая композиция и их применение
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
PH12021550834A1 (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
MX2021015338A (es) Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.
EP4098262A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DIABETES AND METABOLIC DISEASES ASSOCIATED THEREWITH
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности
PH12020551311A1 (en) Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine
TH134004B (th) คอนจูเกทชนิดใหม่ของกรานูโลไซท์ โคโลนี-สติมูเลติ้ง แฟคเตอร์ (g-csf) กับ โพลีเอทธิลีนไกลคอล
NZ724595A (en) Glucokinase activator compositions for the treatment of diabetes
UA59774U (uk) Фармацевтичний засіб для послаблення головного болю на основі парацетамолу